stella
beta
Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2 — Stella
Recruiting
Back to cGVHD trials
Early Phase 1 — The very first tests in people. Usually just a handful of volunteers, to check the treatment is safe enough to keep studying.
Trial locations
(1 site)
China
Shanghai General Hospital, Shanghai
View full record on ClinicalTrials.gov